Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
ROBERT A SEDER · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $528,216 — Mycobacterium tuberculosis (Mtb) is the leading cause of death from infection worldwide. Intradermal (ID) vaccination with BCG has variable efficacy against pulmonary tuberculosis, the major cause of mortality and disease transmission. We showed that the route and dose of BCG vaccination alters circ…
Arya Biragyn · NATIONAL INSTITUTE ON AGING · 2022 · $44,681 — Aging is significant risk factor for dementia and Alzheimers disease (AD). Although aging also dysregulates immune cells, particularly B cells, their role in aging-associated neuro-inflammation remains unclear. By hypothesizing that B-cell function can change in aging, here we continue our study of …
Yun Xing m wang · DIVISION OF BASIC SCIENCES - NCI · 2022 · $2,560,874 — My lab has made progress on several fronts. First, we have developed a novel algorithm and a method using AFM to study RNA conformational dynamics in solution. Briefly, we are now able to directly visualize individual RNA conformers in solution and determine the structures of individu…
Mary N. Carrington · DIVISION OF BASIC SCIENCES - NCI · 2022 · $624,706 — Human immunoglobulin G (IgG) molecules, IgG1, IgG2 and IgG3, exhibit substantial inter-individual variation in their constant heavy chain regions, as discovered by serological methods. This polymorphism is encoded by the IGHG1, IGHG2, and IGHG3 genes and may influence antibody functio…
DAVID MCCORMICK · IIT RESEARCH INSTITUTE · 2022 · $291,405 — PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF PROSTATE CANCER…
JAY EVANS · UNIVERSITY OF MONTANA · 2022 · $2,076,197 — Vaccine Adjuvant Discovery Program: To develop a lead, optimized adjuvanted tuberculosis (TB) vaccine for IM or IN administration using specified adjuvants in combination with recombinant or circRNA TB antigens within the context of a vaccine to prevent TB.…
MARIA FERRARI · BIOQUAL, INC. · 2022 · $584,220 — The development of effective HIV vaccines and other prevention strategies relies on the use of nonhuman primates (NHPs) in preclinical studies. To meet this need, the Simian Vaccine Evaluation Units (SVEUs) provide NHP resources that primarily support preclinical evaluation of AIDS vaccines and prev…
BARRY GAUSE · LEIDOS BIOMEDICAL RESEARCH, INC. · 2022 · $1,527,328 — The Dale and Betty Bumpers Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health, was established to facilitate research in vaccine development and is dedicated to improving global human health through the rigorous pu…
LOUISE C. SHOWE · WISTAR INSTITUTE · 2022 · $221,010 — PROJECT SUMMARY – GENOMICS SHARED RESOURCE The Genomics Shared Resource (GSR) provides state-of-the-art infrastructure and support for integrated functional genomics studies of Cancer Center (CC) investigators. The highly trained staff and their efforts to maintain costs without diminishing service,…
Sallie R. Permar · WEILL MEDICAL COLL OF CORNELL UNIV · 2022 · $343,969 — ABSTRACT – Project 1 There is a critical need to protect adolescents and young adults from HIV infection through the development of an early life vaccine strategy that elicits protective immunity prior to sexual debut. However, to date, efforts to develop a vaccine that can elicit protective broadly…
Mark Morris Davis · STANFORD UNIVERSITY · 2022 · $309,746 — ABSTRACT – Project 2 The goal of Project 2 is to assess T cell responses in the context of proposed studies of: (i) COVID-19 vaccines that utilize novel platforms (mRNA) or adjuvants (Matrix M used in the Novavax vaccine) and (ii) Humans given broad spectrum antibiotics that disrupt their microbiome…
Brent W Segelke · LAWRENCE LIVERMORE NATIONAL SECURITY, LLC · 2022 · $350,659 — PROJECT SUMMARY/ABSTRACT Project Title: Scientific Core 2: Protein Expression and Characterization Core We will establish and operate a protein expression and characterization core that serves the Cooperative Research Center for Nano-Scaffold Vaccines Against Chlamydia trachomatis (Ct) by providing …
NASSER Khaled ALTORKI · WEILL MEDICAL COLL OF CORNELL UNIV · 2022 · $362,579 — PROJECT SUMMARY Computerized chest tomography (CT) lung cancer screening programs have increased the detection of premalignant non-solid (NS) nodules that harbor preinvasive or minimally invasive adenocarcinoma. Given that NS nodules can progress to invasive adenocarcinoma (solid nodules), interce…
CATHERINE MARY O'CONNELL · UNIV OF NORTH CAROLINA CHAPEL HILL · 2022 · $337,380 — In a subset of Chlamydia trachomatis-infected women, the infection escapes immune control and ascends to the upper reproductive tract. There is a fundamental gap in understanding how pathways activated by chlamydial infection lead to immune pathology and reproductive morbidity in women. Its continue…
Nir Hacohen · MASSACHUSETTS GENERAL HOSPITAL · 2022 · $163,120 — Project Summary The overall objective of the U19 is to discover the role of the PD-1 pathway in human immunity by studying the effects of therapeutic PD-1 blockade on immune responses to chronic viruses (Project 1) and preventive vaccines (Project 2). To monitor adaptive immune responses in patients…
Viviana A Simon · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $283,217 — SUMMARY The VIVA Clinical Core B provides the infrastructures needs to support standardized approaches for the recruitment, longitudinal retention and clinical characterization of human subjects enrolled in observational studies. The Core B will facilitate patient centered research through activitie…
SAM ON HO · MOLECULAR EXPRESS, INC. · 2022 · $1,994,571 — Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery …
David A. Hafler · YALE UNIVERSITY · 2022 · $345,355 — Elucidating mechanisms of novel mRNA nanoparticle and adenovirus-viral vector vaccine- induced T and B cell activation at the site of vaccination and lymph nodes is of critical importance. Studying patients with autoimmune disease treated with B cell depletion, we will perform a systems analysis to …
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2022 · $696,115 — Project Summary Administrative Core This Phase II COBRE will continue our center’s work to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approaches for unde…
Steven M Lipkin · WEILL MEDICAL COLL OF CORNELL UNIV · 2022 · $441,081 — Project 1: Project Summary/Abstract Lynch syndrome (LS) affects ~1.2 million Americans and predisposes them to colorectal cancer (CRC) and other malignancies. LS normal cells acquire somatic second mutations and become DNA mismatch repair deficient (MMRD). MMRD tumors have exceptionally high numb…